FULCRUM THERAPEUTICS, INC. Restructuring and Related Cost, Incurred Cost
FULCRUM THERAPEUTICS, INC. (FULC) reported Restructuring and Related Cost, Incurred Cost of $4.32 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. restructuring and related cost, incurred cost for the quarter ending 2026-06-30 was $4.32M.
- FULCRUM THERAPEUTICS, INC. restructuring and related cost, incurred cost for the quarter ending 2025-12-31 was $0.00.
- FULCRUM THERAPEUTICS, INC. restructuring and related cost, incurred cost for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. restructuring and related cost, incurred cost for the quarter ending 2025-06-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. restructuring and related cost, incurred cost for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. restructuring and related cost, incurred cost for fiscal 2022 was $427.00K.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.32M S-4 · filed 2026-09-02 | $4.32M S-4 · filed 2026-09-02 | ||
| 2025-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $0.00 derived: sum of 2 quarters · filed 2026-09-02 | $0.00 derived: sum of 3 quarters · filed 2026-09-02 | $0.00 S-4 · filed 2026-09-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2026-09-02 | $0.00 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $0.00 S-4 · filed 2026-09-02 | $0.00 S-4 · filed 2026-09-02 | ||
| 2024-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $2.06M derived: sum of 2 quarters · filed 2026-09-02 | $2.06M S-4 · filed 2026-09-02 | |
| 2024-09-30 | $2.06M 10-Q · filed 2025-10-29 | $2.06M 10-Q · filed 2025-10-29 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2022-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $427.00K derived: sum of 2 quarters · filed 2024-02-27 | $427.00K 10-K · filed 2024-02-27 | |
| 2022-09-30 | $465.00K 10-Q · filed 2023-11-07 | $465.00K 10-Q · filed 2023-11-07 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |